|
Presenile dementia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To detect how APOE ε4 affects CSF YKL-40 levels in cognitively normal (CN) states, mild cognitive impairment (MCI) and AD dementia, data from 35 CN subjects, 63 patients with MCI, and 11 patients with AD from a cross-sectional study in the Alzheimer's Disease Neuroimaging Initiative (ADNI) database were investigated.
|
31794792 |
2020 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
YKL-40 was increased in dementia compared to healthy controls (p < .01) and MCI (p < .05).
|
30791945 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CSF YKL-40 was significantly higher in patients with HIV-associated dementia compared to all other groups.
|
30678707 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed 5 validated pathophysiological cerebrospinal fluid biomarkers (Aβ<sub>1-42</sub>, t-tau, p-tau<sub>181</sub>, NFL, YKL-40) in 113 participants (healthy controls [N = 20], subjective memory complainers [N = 36], mild cognitive impairment [N = 20], and AD dementia [N = 37], age: 66.7 ± 10.4, 70.4 ± 7.7, 71.7 ± 8.4, 76.2 ± 3.5 years [mean ± SD], respectively) using Density-Based Spatial Clustering of Applications with Noise, which does not require a priori determination of the number of clusters.
|
31585366 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasma YKL-40 in the spectrum of neurodegenerative dementia.
|
31299989 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
High levels of the biomarkers were also associated with cortical thinning (primarily in the precuneus and superior parietal regions) and with subsequent cognitive deterioration in patients without dementia as measured with Mini-Mental State Examination (YKL-40) and Clinical Dementia Rating Sum of Boxes (YKL-40, ICAM-1, VCAM-1 and IL-15).
|
30054439 |
2018 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
While not significantly lower than the AD-Dementia group on YKL-40 and neurogranin, mismatches were also not significantly different from controls.
|
29959263 |
2018 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identified biomarker models able to discriminate FTLD from nondemented controls (MFG-E8, tTau, and A<i>β</i><sub>42</sub>; 78% sensitivity and 83% specificity) and non-FTLD dementia (YKL40, pTau, p/tTau ratio, and age; 90% sensitivity, 78% specificity), which were validated in an independent cohort.
|
30349851 |
2018 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Yet the precise characterization of YKL-40 in dementia cases is missing.
|
29126445 |
2017 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Brain magnetic resonance imaging (MRI) scans were acquired in 110 participants (49 control; 19 preclinical; 27 mild cognitive impairment [MCI] due to AD; 15 mild AD dementia) and CSF concentrations of YKL-40 and sTREM2 were determined.
|
28149943 |
2017 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Determination of YKL-40 CSF concentration may be also helpful in differentiation between types of dementia and in the distinction of patients in the stable phase of MCI from those who progressed to dementia.
|
28183245 |
2017 |